SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 166 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 2.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6 | -14.3% | 314 | 0.0% | 0.00% | – |
| Q1 2024 | $7 | +40.0% | 314 | +29.8% | 0.00% | – |
| Q4 2023 | $5 | +25.0% | 242 | 0.0% | 0.00% | – |
| Q3 2023 | $4 | -20.0% | 242 | 0.0% | 0.00% | – |
| Q2 2023 | $5 | 0.0% | 242 | 0.0% | 0.00% | – |
| Q1 2023 | $5 | -16.7% | 242 | 0.0% | 0.00% | – |
| Q4 2022 | $6 | -99.8% | 242 | +44.9% | 0.00% | – |
| Q3 2022 | $4,000 | +33.3% | 167 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | 0.0% | 167 | 0.0% | 0.00% | – |
| Q1 2022 | $3,000 | -25.0% | 167 | 0.0% | 0.00% | – |
| Q4 2021 | $4,000 | +33.3% | 167 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | +50.0% | 167 | +79.6% | 0.00% | – |
| Q2 2021 | $2,000 | 0.0% | 93 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 93 | +20.8% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 77 | -43.0% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 135 | 0.0% | 0.00% | – |
| Q2 2018 | $1,000 | -50.0% | 135 | 0.0% | 0.00% | – |
| Q1 2018 | $2,000 | – | 135 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $19,588,000 | 3.91% |
| Ghost Tree Capital, LLC | 575,000 | $10,988,000 | 3.21% |
| Avidity Partners Management LP | 4,823,400 | $92,175,000 | 2.04% |
| BVF INC/IL | 2,486,429 | $47,516,000 | 1.85% |
| FRAZIER MANAGEMENT LLC | 1,188,135 | $22,705,000 | 1.82% |
| Nantahala Capital Management | 2,657,159 | $50,778,000 | 1.60% |
| Boxer Capital, LLC | 2,287,782 | $43,720,000 | 1.53% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,939,000 | 1.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 750,603 | $14,344,000 | 1.20% |
| PFM Health Sciences, LP | 1,856,738 | $35,482,000 | 1.04% |